Physician profile
Yan Cheng
NPI 1548558125
$845.56
in general payments reported to CMS, 2019-2025
19 companies · $19.36 in 2025
The $19.36 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.96 · 2020: $28.51 · 2021: $214 · 2022: $19.55 · 2023: $305 · 2024: $170 · 2025: $19.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.55 |
| Education | $151.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $132.14 | 2023 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2023 | |
| Seagen INC. | $99.95 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2021 | |
| Merck Sharp & Dohme LLC | $78.22 | 2019-2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $67.97 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $51.06 | 2024 | Libtayo |
| Amgen INC. | $28.22 | 2019-2021 | |
| Puma Biotechnology, INC. | $23.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2023 | |
| Stemline Therapeutics INC. | $19.55 | 2022 | |
| Lilly USA, LLC | $19.36 | 2025 | Verzenio, Jaypirca |
| Exelixis INC. | $18.09 | 2024 | Cabometyx |
| Pfizer INC. | $17.00 | 2024 | |
| Janssen Biotech, INC. | $16.00 | 2024 | Tecvayli, Darzalex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $15.19 | 2023 | Pyrukynd |
| Astrazeneca Pharmaceuticals Lp | $14.94 | 2019 | |
| Incyte Corporation | $14.06 | 2020 | |
| Fortovia Therapeutics, INC. | $9.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.